Enanta Pharmaceuticals (ENTA)

• Market cap: $369M
• 1 day: -5.29%
• 5 days: -3.86%
• 1 month: -8.3%
• 3 months: -14.59%
• 6 months: 70.24%
• Year to date: -11.93%
• 1 year: 85.94%
• 5 years: -75.74%
• 10 years: -56.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Employees: 120